Showing results (161-170 of 254) with videos related to
Sort By:
Pageof 26
The Pediatric Infectious Disease Journal|April 14, 2020
Prevalence of High-risk Nonavalent Vaccine-type Human Papillomavirus Infection Among Unvaccinated, Sexually Active Asian Female Adolescents With and Without Perinatally Acquired HIV InfectionSirintip Sricharoenchai, Stephen J Kerr, Sivaporn Gatechompol, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097Diana F Clarke, Jos Lommerse, Edward P Acosta, et al.The Pediatric Infectious Disease Journal|February 12, 2009
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacyEllen Gould Chadwick, Jorge Pinto, Ram Yogev, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2010
Survival of HIV-infected children: a cohort study from the Asia-Pacific regionPagakrong Lumbiganon, Azar Kariminia, Linda Aurpibul, et al.International Journal of STD & AIDS|June 21, 2017
Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity TransferNicole L De La Mata, Penh S Ly, Oon T Ng, et al.AIDS (London, England)|July 24, 2019
Association between zidovudine-containing antiretroviral therapy exposure in utero and leukocyte telomere length at birthYoujin Wang, Sean S Brummel, Erin Beilstein-Wedel, et al.AIDS (London, England)|March 3, 2012
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infantsGeorge K Siberry, Paige L Williams, Hermann Mendez, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 30, 2016
Association of Dyslipidemia and Glucose Abnormalities With Antiretroviral Treatment in a Cohort of HIV-Infected Latin American ChildrenMachline P Paganella, Rachel A Cohen, Donald R Harris, et al.Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 14, 2019
A Longitudinal Study of Behavioral Risk, Adherence, and Virologic Control in Adolescents Living With HIV in AsiaJeremy L Ross, Sirinya Teeraananchai, Pagakrong Lumbiganon, et al.Pageof 26